15
Sep 2026
KAIST team uncovers how neurons deliver RNA to distant regions
Much like a courier reading an address on a package, neurons must deliver RNA to the precise locations where it is needed.
Stay Informed!
15
Sep 2026
Wearable electroceutical platform enables remote wireless pain management
A "wearable electroceutical" has been developed that could reduce the need to visit a hospital or rely on painkillers every time pain occurs.
15
Sep 2026
Wearable electroceutical platform enables remote wireless pain management
A "wearable electroceutical" has been developed that could reduce the need to visit a hospital or rely on painkillers every time pain occurs.
15
Sep 2026
Nationwide safety program successfully cuts hospital-onset MRSA infections
A large-scale, federally funded quality improvement program developed in collaboration with infection prevention experts at the Johns Hopkins Armstrong Institute for Patient Safety and Quality was associated with a 65% reduction in hospital-onset bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA) among participating hospital units.
15
Sep 2026
Study reinforces generalizability of perioperative azithromycin for unplanned cesarean deliveries
Infection can develop in up to 10-20% of patients after a Cesarean delivery, and the risk nearly doubles for those who have an unplanned cesarean delivery, such as those performed during labor.
15
Sep 2026
Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades
A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).
15
Sep 2026
Stage 1 findings support continued pivotal phase evaluation of gotistobart
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.
15
Sep 2026
Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings
Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
15
Sep 2026
Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers
Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
15
Sep 2026
Investigational anti-CTLA-4 antibody improves survival in metastatic squamous NSCLC
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.
